JP2015521189A - ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体 - Google Patents

ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体 Download PDF

Info

Publication number
JP2015521189A
JP2015521189A JP2015513183A JP2015513183A JP2015521189A JP 2015521189 A JP2015521189 A JP 2015521189A JP 2015513183 A JP2015513183 A JP 2015513183A JP 2015513183 A JP2015513183 A JP 2015513183A JP 2015521189 A JP2015521189 A JP 2015521189A
Authority
JP
Japan
Prior art keywords
optionally substituted
alkyl
compound
optionally
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015513183A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015521189A5 (enExample
Inventor
アンドレア ヴォルカーシュトルファー
アンドレア ヴォルカーシュトルファー
オリヴィエ ソラル
オリヴィエ ソラル
ノルベルト ハンドラー
ノルベルト ハンドラー
ステファン キューザック
ステファン キューザック
ティボー ソーベートル
ティボー ソーベートル
セリーヌ ミショー−シモン
セリーヌ ミショー−シモン
クリストフ モリス
クリストフ モリス
ブルーノ ジェトラン
ブルーノ ジェトラン
ティエリー ランジェ
ティエリー ランジェ
マーク スミス
マーク スミス
ソン−サウ ソ
ソン−サウ ソ
ディルク クラッセン−ホーベン
ディルク クラッセン−ホーベン
ヘルムート ブッシュマン
ヘルムート ブッシュマン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
European Molecular Biology Laboratory
Original Assignee
European Molecular Biology Laboratory
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by European Molecular Biology Laboratory filed Critical European Molecular Biology Laboratory
Publication of JP2015521189A publication Critical patent/JP2015521189A/ja
Publication of JP2015521189A5 publication Critical patent/JP2015521189A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2015513183A 2012-05-23 2013-05-23 ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体 Pending JP2015521189A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650725P 2012-05-23 2012-05-23
US61/650,725 2012-05-23
PCT/EP2013/060634 WO2013174931A1 (en) 2012-05-23 2013-05-23 7-oxo-4,7 -dihydro- pyrazolo [1, 5 -a] pyrimidine derivatives which are useful in the treatment, amelioration or prevention of a viral disease

Publications (2)

Publication Number Publication Date
JP2015521189A true JP2015521189A (ja) 2015-07-27
JP2015521189A5 JP2015521189A5 (enExample) 2016-07-14

Family

ID=48669866

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015513183A Pending JP2015521189A (ja) 2012-05-23 2013-05-23 ウイルス性疾患の治療、改善又は予防に有用な７−オキソ−４，７−ジヒドロ−ピラゾロ［１，５−ａ］ピリミジン誘導体

Country Status (11)

Country Link
US (2) US20130317021A1 (enExample)
EP (1) EP2861232A1 (enExample)
JP (1) JP2015521189A (enExample)
KR (1) KR20150014506A (enExample)
CN (1) CN104507481B (enExample)
BR (1) BR112014029006A2 (enExample)
CA (1) CA2874253A1 (enExample)
HK (1) HK1204987A1 (enExample)
MX (1) MX2014014109A (enExample)
RU (1) RU2014146778A (enExample)
WO (1) WO2013174931A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517555A (ja) * 2012-05-23 2015-06-22 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP2021514347A (ja) * 2018-01-31 2021-06-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012178125A1 (en) 2011-06-22 2012-12-27 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
LT3418281T (lt) 2012-12-07 2021-01-11 Vertex Pharmaceuticals Inc. Pirazolo[1,5-a]pirimidinai, naudotini kaip atr kinazės inhibitoriai, skirti vėžinių ligų gydymui
RU2015143517A (ru) * 2013-03-13 2017-04-19 Дженентек, Инк. Пиразолсодержащие соединения и их применения
EP2970288A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of atr kinase
WO2014143240A1 (en) 2013-03-15 2014-09-18 Vertex Pharmaceuticals Incorporated Fused pyrazolopyrimidine derivatives useful as inhibitors of atr kinase
EP2970289A1 (en) 2013-03-15 2016-01-20 Vertex Pharmaceuticals Inc. Compounds useful as inhibitors of atr kinase
HUE046727T2 (hu) 2013-12-06 2020-03-30 Vertex Pharma Az ATR-kináz inhibitoraként használható vegyület, 2-amino-6-fluoro-N-[5-fluoro-piridin-3-IL]-pirazolo-[1,5-A]-pirimidin-3-karboxamid, ennek elõállítása, különbözõ szilárd formái és ezek radioaktív nyomjelzett származékai
ES2777608T3 (es) 2014-06-05 2020-08-05 Vertex Pharma Derivados radiomarcados de un compuesto de 2-amino-6-fluoro-N-[5-fluoro-piridin-3-il]-pirazolo[1,5-a]pirimidin-3-carboxamida útiles como inhibidores de ATR cinasa, la preparación de dicho compuesto y diferentes formas sólidas del mismo
US11179394B2 (en) 2014-06-17 2021-11-23 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of Chk1 and ATR inhibitors
AU2015284307A1 (en) 2014-07-01 2017-02-02 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
CA2953862A1 (en) 2014-07-07 2016-01-14 F. Hoffmann-La Roche Ag Dihydropyridopyrazine-1,8-diones and their use in the treatment, amelioration or prevention of viral diseases
CN107709321A (zh) 2015-04-28 2018-02-16 盐野义制药株式会社 经取代的多环性吡啶酮衍生物及其前药
US20170081331A1 (en) * 2015-09-18 2017-03-23 F. Hoffmann-La Roche Ag Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
US11464774B2 (en) 2015-09-30 2022-10-11 Vertex Pharmaceuticals Incorporated Method for treating cancer using a combination of DNA damaging agents and ATR inhibitors
HK1254961A1 (en) 2015-12-15 2019-08-02 Shionogi & Co., Ltd. Medicine for treating influenza characterized by comprising combination of cap-dependent endonuclease inhibitor with anti-influenza drug
JP6957535B2 (ja) 2016-06-29 2021-11-02 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ピリダジノンベースの広域スペクトル抗インフルエンザ阻害剤
US10759814B2 (en) 2016-08-10 2020-09-01 Shionogi & Co., Ltd. Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof
WO2018071282A1 (en) * 2016-10-12 2018-04-19 Merck Sharp & Dohme Corp. Kdm5 inhibitors
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
US10738056B2 (en) 2017-09-15 2020-08-11 Aduro Biotech Inc. Pyrazolopyrimidinone compounds and uses thereof
AR125966A1 (es) 2021-05-26 2023-08-30 Novartis Ag Nuevos compuestos bicíclicos y sus usos
CN113620977B (zh) * 2021-08-24 2024-02-02 江苏弘和药物研发有限公司 一种噻唑烷并嘧啶酮乙酸的合成方法
CN117304133B (zh) * 2023-09-26 2026-03-17 华南农业大学 一种具有噻唑侧链的截短侧耳素衍生物及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502770A (ja) * 2000-07-12 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての複素環カルボキシアミド
JP2005533040A (ja) * 2002-06-04 2005-11-04 ネオジェネシス ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物
WO2011035518A1 (zh) * 2009-09-23 2011-03-31 辽宁利锋科技开发有限公司 嘧啶衍生物和类似物及其制备方法和用途
JP2015517555A (ja) * 2012-05-23 2015-06-22 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5475109A (en) 1994-10-17 1995-12-12 Merck & Co., Inc. Dioxobutanoic acid derivatives as inhibitors of influenza endonuclease
JP4953297B2 (ja) 2004-09-15 2012-06-13 塩野義製薬株式会社 Ｈｉｖインテグラーゼ阻害活性を有するカルバモイルピリドン誘導体
US20070072831A1 (en) 2005-05-16 2007-03-29 Gilead Sciences, Inc. Integrase inhibitor compounds
US20110112086A1 (en) * 2006-06-08 2011-05-12 Cylene Pharmaceuticals, Inc. Pyridinone analogs
US8835461B2 (en) 2009-03-26 2014-09-16 Shionogi & Co., Ltd. Substituted 3-hydroxy-4-pyridone derivative
TWI518084B (zh) 2009-03-26 2016-01-21 鹽野義製藥股份有限公司 哌喃酮與吡啶酮衍生物之製造方法
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004502770A (ja) * 2000-07-12 2004-01-29 ファルマシア・アンド・アップジョン・カンパニー 抗ウイルス剤としての複素環カルボキシアミド
JP2005533040A (ja) * 2002-06-04 2005-11-04 ネオジェネシス ファーマシューティカルズ インコーポレイテッド 抗ウイルス剤としてのピラゾロ［１，５ａ］ピリミジン化合物
WO2011035518A1 (zh) * 2009-09-23 2011-03-31 辽宁利锋科技开发有限公司 嘧啶衍生物和类似物及其制备方法和用途
JP2015517555A (ja) * 2012-05-23 2015-06-22 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RUSSIAN CHEMICAL BULLETIN, INTERNATIONAL EDITION, 2010, VOL.59(1), P.136-143, JPN6017005615, ISSN: 0003503679 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015517555A (ja) * 2012-05-23 2015-06-22 ザヴィラ ファーマシューティカルズ ゲーエムベーハー ７−オキソ−チアゾロピリジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP2021514347A (ja) * 2018-01-31 2021-06-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン
JP7305658B2 (ja) 2018-01-31 2023-07-10 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー 抗ｒｓｖ活性を有するシクロアルキル置換ピラゾロピリミジン

Also Published As

Publication number Publication date
KR20150014506A (ko) 2015-02-06
BR112014029006A2 (pt) 2017-06-27
CN104507481B (zh) 2017-08-04
CA2874253A1 (en) 2013-11-28
CN104507481A (zh) 2015-04-08
HK1204987A1 (en) 2015-12-11
EP2861232A1 (en) 2015-04-22
US20160367557A1 (en) 2016-12-22
WO2013174931A1 (en) 2013-11-28
RU2014146778A (ru) 2016-07-10
MX2014014109A (es) 2016-03-31
US20130317021A1 (en) 2013-11-28

Similar Documents

Publication Publication Date Title
CN104507481B (zh) 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物
CN104334563B (zh) 7‑氧代‑噻唑并吡啶碳酸衍生物和它们在治疗、改善或预防病毒疾病中的用途
JP2015524457A (ja) ジヒドロキシピリミジン炭酸誘導体及びウイルス性疾患の治療、改善又は予防における使用
JP6033873B2 (ja) ピリミジン−４−オン誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP6047168B2 (ja) ヘテロアリールヒドロキサム酸誘導体及びウイルス性疾患の治療、改善又は予防におけるその使用
JP2017521424A (ja) ウイルス疾患の治療、改善又は予防におけるジヒドロピリドピラジン−１，８−ジオン及びそれらの使用
TW201726678A (zh) 嘧啶酮衍生物及其於治療、改善或預防病毒性疾病之用途
JP2016508145A (ja) ピリドン誘導体及びウイルス性疾患の治療、改善又は予防におけるそれらの使用
WO2017046318A1 (en) Triazolones derivatives for use in the treatment, amelioration or prevention of a viral disease
EP2945945B1 (en) Naphthyridinone derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017046362A1 (en) Pyrazolopyrazines and their use in the treatment, amelioration or prevention of a viral disease
EP4387629A1 (en) 6-substituted- and 6,7-disubstituted-7-deazapurine ribonucleoside analogues
JP2017521423A (ja) ピリドピラジン化合物及びインフルエンザの治療、改善又は予防におけるそれらの使用
HK1205128B (en) 7-oxo-thiazolopyridine carbonic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease
WO2017046350A1 (en) Triazolones derivatives and their use in the treatment, amelioration or prevention of a viral disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20150120

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150120

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150204

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A525

Effective date: 20150120

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20150120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160520

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20170228

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170522

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20180206